Data from patients treated with phase I study drugs targeting the PI3K and/or MAPK pathways revealed that CRC patients harboring mutations in both pathways had tumor regression ranging between 2% and 64% when treated with PI3K and MAPK inhibitors. The gene discussed is PIK3CA; the disease is neoplasm.